BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dejman A, Ladino MA, Roth D. Treatment and management options for the hepatitis C virus infected kidney transplant candidate. Hemodial Int 2018;22 Suppl 1:S36-44. [PMID: 29694726 DOI: 10.1111/hdi.12646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Bruchfeld A, Lindahl K. Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease. Semin Dial 2019;32:135-40. [PMID: 30475421 DOI: 10.1111/sdi.12762] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Abaalkhail F, Al-hamoudi W, Altraif I, Mohamed H, Aleid H, Broering D, Alqahtani S. Treatment with Grazoprevir/Elbasvir in Post-kidney Transplant Patients with Hepatitis C Virus Genotype 4 Infection. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.110260] [Reference Citation Analysis]
3 George N, Liapakis A, Korenblat KM, Li T, Roth D, Yee J, Fowler KJ, Howard L, Liu J, Politi MC. A Patient Decision Support Tool for Hepatitis C Virus and CKD Treatment. Kidney Med 2019;1:200-6. [PMID: 32734200 DOI: 10.1016/j.xkme.2019.06.003] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Malyszko J, Zawierucha J, Marcinkowski W, Prystacki T, Dryl-Rydzynska T, Malyszko JS, Matuszkiewicz-Rowinska J. The prevalence of hepatitis C and B among patients on hemodialysis and on renal transplantation waiting list in Poland has significantly decreased during the last 10 years. Int Urol Nephrol 2018;50:1555-6. [PMID: 29868940 DOI: 10.1007/s11255-018-1897-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]